INS and type 2 diabetes mellitus: The trials include T2DM participants treated with lifestyle intervention alone (SURPASS-1, SURPASS-J mono) or oral agents in the form of Metformin, Sulfonylurea, Pioglitazone, SGLT2-inhibitor (SURPASS-2, SURPASS-3, SURPASS-4, SURPASS-J combo, SURPASS-AP combo) and/or insulin (SURPASS-5, SURPASS-6) [43–51].